Covid: Remdesivir ‘has little or no effect’ on survival, says WHO – BBC News

Anti-viral drug remdesivir has little to no effect on Covid patients’ chances of survival, a study from the World Health Organization (WHO) has found.

The WHO trial evaluated four potential medications for Covid-19, including remdesivir and hydroxychloroquine.

Remdesivir was among the first to be used to treat coronavirus, and was recently given to US President Donald Trump when he was in hospital.

The drug’s manufacturer Gilead rejected the findings of the trial.

In a statement, Gilead said the findings of the study were “inconsistent” with others, and that it was “concerned” that the results have yet to be reviewed.

What did the WHO study find?

For its Solidarity clinical trial, the WHO tested the effects four potential treatments – remdesivir, an Ebola drug, was one, but they also looked at malaria drug hydroxychloroquine, auto-immune drug interferon, and the HIV drug combination of lopinavir and ritonavir.

Dexamethasone, a low-cost steroid now widely used on Covid patients in intensive care in the UK, was not included in this study.

The four drugs were tested with 11,266 adult patients in total, across 500 hospitals in more than 30 different countries.

The results, which are yet to be peer-reviewed, suggest that none of these treatments has a substantial effect on mortality or on the length of time spent in hospital, the WHO said on Thursday.

…(read more).

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s